Brief: Nuvasive Receives Latest CE Mark Approval For Pulse Platform And Starts Global Clinical Evaluations
30/06/2021 12:14
June 30 (Reuters) - NuVasive Inc NUVA.O :
* NUVASIVE RECEIVES LATEST CE MARK APPROVAL FOR PULSE
PLATFORM AND
STARTS GLOBAL CLINICAL EVALUATIONS
Source text for Eikon: ID:nPn2stghsa
Further company coverage: NUVA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NuVasive
See all newsJackson Financial to join small-cap S&P 600; shares climb
NuVasive Inc reports results for the quarter ended in June - Earnings Summary
Brief: NuVasive Q2 Adjusted EPS USD 0.56 Vs. IBES Estimate USD 0.55
NuVasive Inc expected to post earnings of 55 cents a share - Earnings Preview
Brief: NuVasive Borrows $350 Mln In Revolving Loans Under 2020 Facility